Q BioMed Inc. (OTCMKTS:QBIO – Get Rating) was the recipient of a significant decline in short interest in the month of April. As of April 30th, there was short interest totalling 10,500 shares, a decline of 41.7% from the April 15th total of 18,000 shares. Based on an average daily trading volume, of 958,000 shares, […]
Amicus Therapeutics (NASDAQ:FOLD – Get Rating) and Q BioMed (OTCMKTS:QBIO – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership. Profitability This table compares Amicus Therapeutics and Q BioMed’s net […]
Should You Buy or Sell Amicus Therapeutics Stock? Get The Latest FOLD Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Company s Liver Cancer Drug Candidate IP Portfolio strengthened
Company provides operational update on strategic opportunities
NEW YORK, April 14, 2023 /PRNewswire/ Q BioMed Inc. a biotech. | April 14, 2023
/PRNewswire/ The liver cancer drugs market size is forecast to increase by USD 5.29 billion from 2021 to 2026, at a CAGR of 14.67%, according to the recent.